Good Life Advisors LLC Sells 6,748 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Good Life Advisors LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 58.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,868 shares of the biopharmaceutical company's stock after selling 6,748 shares during the quarter. Good Life Advisors LLC's holdings in Gilead Sciences were worth $450,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. State Street Corp increased its position in shares of Gilead Sciences by 1.4% during the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock valued at $5,044,795,000 after purchasing an additional 841,776 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the last quarter. FMR LLC increased its position in shares of Gilead Sciences by 79.4% during the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock valued at $2,302,119,000 after purchasing an additional 574,421 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Gilead Sciences by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company's stock valued at $650,009,000 after purchasing an additional 224,960 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $0.08 during midday trading on Friday, reaching $109.95. 9,729,048 shares of the stock traded hands, compared to its average volume of 7,379,648. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market capitalization of $137.03 billion, a PE ratio of 297.16, a P/E/G ratio of 0.71 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $111.03. The company's 50 day moving average is $95.41 and its 200 day moving average is $88.73.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is presently 832.43%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 713,000 shares of company stock worth $67,945,181. Company insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Citigroup initiated coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 price target for the company. Bank of America reiterated a "buy" rating and set a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Truist Financial boosted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research note on Friday, November 8th. Maxim Group downgraded Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Finally, BMO Capital Markets boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $102.08.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.